SEARCH

SEARCH BY CITATION

References

  • 1
    Herold KC, Gitelman SE, Masharani U et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:17631769.
  • 2
    Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614623.
  • 3
    Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487497.
  • 4
    Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412419.
  • 5
    Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 2011; 60:18.
  • 6
    Bach JF. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011; 378:459460.
  • 7
    Chatenoud L. Diabetes: type 1 diabetes mellitus – a door opening to a real therapy? Nat Rev Endocrinol 2011; 7:564566.
  • 8
    Vandemeulebroucke E, Keymeulen B, Decochez K et al. Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 2010; 53:3644.
  • 9
    Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care 2009; 32:17691782.
  • 10
    Skyler JS, Brown D, Chase HP et al. Effect of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:16851691.
  • 11
    Gale EAM, Bingley PJ, Knip M et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised intervention before onset of type 1 diabetes. Lancet 2004; 363:925931.
  • 12
    Lachin JM, McGee PL, Greenbaum CJ et al. Sample size requirements for studies of treatment effects on beta cell function in newly diagnosed type 1 diabetes. PLoS ONE 2011; 6:e26471.
  • 13
    Bingley PJ, Bonifacio E, Gale EA. Can we really predict IDDM? Diabetes 1993; 42:213220.
  • 14
    Knip M, Korhonen S, Kulmala P et al. Prediction of type 1 diabetes in the general population. Diabetes Care 2010; 33:12061212.
  • 15
    Simell O, Winter WE, Schatz D. Enhancing the understanding of pre-type 1 diabetes in the general population. Diabetes Care 2010; 33:14031405.
  • 16
    Robertson RP. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 2007; 56:24202424.
  • 17
    Sosenko JM, Palmer JP, Rafkin LE et al. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care 2010; 33:620625.
  • 18
    Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:22692274.
  • 19
    Achenbach P, Bonifacio E, Koczwara K et al. Natural history of type 1 diabetes. Diabetes 2005; 54 (Suppl. 2):S25S31.
  • 20
    Verge CF, Gianani R, Kawasaki E et al. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45:926933.
  • 21
    De Grijse J, Asanghanwa M, Nouthe B et al. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010; 53:517524.
  • 22
    Gorus FK. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev 1997; 13:247274.
  • 23
    Wenzlau JM, Frisch LM, Gardner TJ et al. Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diabetes Rep 2009; 9:105112.
  • 24
    Vermeulen I, Weets I, Asanghanwa M et al. Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 2011; 34:17601765.
  • 25
    Leslie RD. Predicting adult-onset autoimmune diabetes: clarity from complexity. Diabetes 2010; 59:330331.
  • 26
    Vermeulen I, Weets I, Costa O et al. An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age. Diabetologia 2012; 55:413420.
  • 27
    Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:25982608.
  • 28
    Vandewalle CL, Coeckelberghs MI, De Leeuw IH et al. Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 1997; 20:15561561.
  • 29
    Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:11831197.
  • 30
    Weets I, Van Autreve J, Van der Auwera BJ et al. Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index. Diabetologia 2001; 44:4047.
  • 31
    Van der Auwera BJ, Schuit FC, Weets I et al. Relative and absolute HLA-DQA1–DQB1 linked risk for developing type 1 diabetes before 40 years of age in the Belgian population: implications for future prevention studies. Hum Immunol 2002; 63:4050.
  • 32
    Truyen I, De Pauw P, Jørgensen PN et al. Proinsulin levels and the proinsulin: C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 2005; 48:23222329.
  • 33
    Decochez K, Truyen I, Van der Auwera B et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005; 48:687694.
  • 34
    Steck AK, Johnson K, Barriga KJ et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes. Diabetes Autoimmunity Study in the Young. Diabetes Care 2011; 34:13971399.
  • 35
    Bonifacio E, Pflüger M, Marienfeld S et al. Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA(1c). Diabetologia 2008; 51:12451252.
  • 36
    Long AE, Gooneratne AT, Rokni S et al. The role of autoantibodies to zinc transporter 8 in prediction of type 1 diabetes in relatives: lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) cohort. J Clin Endocrinol Metab 2012; 97:632637.
  • 37
    Veijola R, Reijonen H, Vähäsalo P et al. HLA-DQB1-defined genetic susceptibility, beta cell autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. J Clin Invest 1996; 98:24892495.
  • 38
    Siljander HT, Veijola R, Reunanen A, Virtanen SM, Åkerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007; 50:22722275.
  • 39
    Mahon JL, Dupre J. The limitations of clinical trials for preventions of IDDM. Diabetes Care 1997; 20:10271033.
  • 40
    Gorus FK, Pipeleers DG. Belgian Diabetes Registry. Prospects for predicting and stopping the development of type 1 diabetes. Best Pract Res Clin Endocrinol Metab 2001; 15:371389.
  • 41
    Yu L, Liu Y, Miao D et al. Triple chimeric islet autoantigen IA-2-ZnT8WR to facilitate islet autoantibody determination. J Immunol Methods 2010; 353:2023.